Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 57Pancreatic Neoplasms 39Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 20Neoplasms 17Neoplasm Metastasis 11Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Ovarian Neoplasms 8Melanoma 7Head and Neck Neoplasms 6Breast Neoplasms, Male 6Adenocarcinoma 6Urinary Bladder Neoplasms 5Inflammatory Breast Neoplasms 5Carcinoma 5Sarcoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Pancreatic Diseases 4Fallopian Tube Neoplasms 4Cholangiocarcinoma 4Carcinoma, Ovarian Epithelial 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Pancreatic Adenocarcinoma 3Esophageal Neoplasms 3Endocrine System Diseases 3Endocrine Gland Neoplasms 3Digestive System Neoplasms 3Digestive System Diseases 3

Interventions

Gemcitabine 4Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3PEGPH20 2napabucasin 1folfirinox 1Radiotherapy 1Enoxaparin 1Dexamethasone 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Carcinoma, Pancreatic Ductal × Albumin-Bound Paclitaxel × Clear all
NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT01839487 2020-07-20

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Halozyme Therapeutics

Phase 2 Completed
279 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT02715804 2020-07-14

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Halozyme Therapeutics

Phase 3 Terminated
492 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡